Stada Arzneimittel AGSAZX.N:GER

1.055 / 3.41 %
Close in EURToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Feb 05 2016 16:35 GMT.


On Friday, Stada Arzneimittel AG (SAZX.N:GER) closed at 29.87, 12.29% above the 52 week low of 26.60 set on Feb 19, 2015.

52-week range
Feb 19 2015
Dec 30 2015
Markit short selling activity
Day high31.08
Day low29.76
Previous close30.93
Average volume274.31k
Shares outstanding62.34m
Free float62.34m
P/E (TTM)33.17
Market cap1.86bn EUR
EPS (TTM)0.9004 EUR
Annual div (IAD)0.4859 EUR
Annual div yield (IAD)1.63%
Div ex-dateJun 04 2015
Div pay-dateJun 04 2015
Data delayed at least 15 minutes, as of Feb 05 2016 16:35 GMT.

Comparative analysis

Past 90 days
1 week1 month6 months1 year5 years
Stada Arzneimittel AG-6.05 %-18.97 %-12.00 %+5.53 %+5.73 %
DEUTSCHE BORSE DAX INDEX-5.22 %-9.93 %-19.19 %-14.85 %+28.69 %
DE/HEALTH CARE-8.26 %-13.74 %-31.71 %-16.16 %+45.74 %
DE/PHARMACEUTICALS-7.10 %-13.79 %-39.98 %-28.42 %+44.71 %
Data delayed at least 15 minutes, as of Feb 05 2016 16:35 GMT.
© Thomson Reuters Click for restrictions.

All markets data located on is subject to the FT Terms & Conditions.

All content on is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.

Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.